6533b824fe1ef96bd1280a10

RESEARCH PRODUCT

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

Giuseppe RubiniAnna Giulia NappiAlessio FarcomeniMaria LicariManlio MasciaSusanna NuvoliAngela SpanuFabio MonariRenato CostaValentina LavelliElisa Lodi RizziniViviana FrantellizziMaria Antonietta RicciValeria DionisiLuca CindoloGiuseppe De Vincentis

subject

MaleRadium-223Oncologymedicine.medical_specialtyRadium-223 dichlorideRadium-223 dichloride; bone health agents; mCRPC; overall survival; prostate canceroverall survivalBone healthBone and Bones030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineBone MarrowInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingRadium-223 DichlorideNeoplasm MetastasisAgedL-Lactate DehydrogenaseRadiological and Ultrasound Technologybusiness.industrymCRPCAlkaline Phosphataseprostate cancermedicine.diseaseSurvival AnalysisRANK Ligand InhibitorProstatic Neoplasms Castration-ResistantDenosumabMulticenter studybone health agents030220 oncology & carcinogenesisSettore SECS-S/01businessRadiummedicine.drug

description

Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.430 consecutive patients treated with Radium-223 alone or in combination with BHA, affected by mCRPC, from January 2015 to July 2019 in six Italian Nuclear Medicine Units, were included. Furthermore, data were collected at baseline, after every Radium-223 administration, and during follow-up, at 3 and 6 months and 1 year after the 6th cycle. Clinical data have been evaluated before starting treatment with Radium-223 and at the end of treatment and/or at progression. Patients who received target bone therapy with BHA before Radium-223 treatment together with patients who did not receive this therapy at all (NO BHA GROUP), were compared to patients treated with concomitant Radium-223 and BHA (BHA GROUP).In univariate models (At univariate analysis, our data showed that NO BHA GROUP and BHA GROUP differ in OS by 7 months (95%CI: (1-16.4),

yearjournalcountryeditionlanguage
2020-11-03International Journal of Radiation Biology
https://doi.org/10.1080/09553002.2020.1838655